

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8325080

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AMPLYX PHARMACEUTICALS, INC.	11/13/2023
RECEIVING PARTY DATA	
Name:	BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL
Street Address:	HEGENHEIMERMATTWEG 167B
City:	ALLSCHWIL
State/Country:	SWITZERLAND
Postal Code:	4123
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	16770476
Application Number:	17934629
Application Number:	17271020
Application Number:	17908079
Application Number:	18002012
Application Number:	17253885
CORRESPONDENCE DATA	
Fax Number:	(973)596-0545
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	973-596-4500
Email:	IPDocket@gibbonslaw.com
Correspondent Name:	IP DOCKET ADMINISTRATOR
Address Line 1:	ONE GATEWAY CENTER
Address Line 2:	GIBBONS P.C.
Address Line 4:	NEWARK, NEW JERSEY 07102
ATTORNEY DOCKET NUMBER:	104610-110195
NAME OF SUBMITTER:	XIANGJING ZHAN
SIGNATURE:	/Xiangjing Zhan/
DATE SIGNED:	12/12/2023

Total Attachments: 20

source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page1.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page2.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page3.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page4.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page5.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page6.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page7.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page8.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page9.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page10.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page11.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page12.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page13.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page14.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page15.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page16.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page17.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page18.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page19.tif
source=Project Palomino - Assignment of Registered Intellectual Property 13 November 2023#page20.tif

ASSIGNMENT OF REGISTERED INTELLECTUAL PROPERTY

THIS ASSIGNMENT OF REGISTERED INTELLECTUAL PROPERTY (this “*Assignment*”) is entered into as of 13 November, 2023 by and between Amplyx Pharmaceuticals, Inc., a Delaware corporation (“*Assignor*”) with its principal place of business at 66 Hudson Boulevard East New York, NY 10001-2192, United States of America and Basilea Pharmaceutica International AG, Allschwil, a Swiss Corporation (“*Assignee*”) with its principal place of business at Hegenheimermattweg 167b, 4123 Allschwil, Switzerland. Except as otherwise defined herein, capitalized terms used in this Assignment shall have the meaning ascribed to them in the Asset Purchase Agreement dated as of 13 November, 2023 (the “*Purchase Agreement*”), by and among Assignor, Assignee, and the other parties named therein.

WHEREAS, pursuant to the Purchase Agreement, Assignor and the Transferring Affiliates have agreed to sell, convey, assign, transfer and deliver the Purchased Assets to Assignee;

WHEREAS, the Purchased Assets include certain items of Intellectual Property; and

WHEREAS, in accordance with the Purchase Agreement, Assignor desires to sell, convey, assign, transfer and deliver to Assignee, and Assignee desires to accept such sale, conveyance, assignment, transfer and delivery of all of Assignor’s worldwide right, title and interest in and to the patent applications and patents set forth on Schedule A attached hereto (the “*Purchased Patents*”).

NOW, THEREFORE, in exchange for the consideration set forth in the Purchase Agreement and the mutual covenants contained herein and in the Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Assignor does hereby sell, convey, assign, transfer and deliver to Assignee, and Assignee hereby accepts such sale, conveyance, assignment, transfer and delivery of all of Assignor’s worldwide right, title and interest in and to:

(a) the Purchased Patents; and

(b) the right (whether at law, in equity, by contract or otherwise) to enjoy or otherwise exploit any of the Purchased Patents, including all rights to sue for past, current or future infringement or misappropriation of, or damage or injury to, any of (a) the Purchased Patents, whether known or unknown and whether arising before or after the date of this Assignment, and (b) any continuations, divisions, reissues, reexaminations, registrations, renewals and extensions (including supplementary protection certificates and the like) of any such Purchased Patents that may hereafter be secured by Assignee under the Laws now or hereafter in effect in the United States and worldwide.

2. The Purchased Patents and all right, title and interest in and to the same are to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this Assignment not been made.

3. Assignor agrees to execute all documents necessary to perfect such right, title, and interest in and to Assignee, its successors, assigns, and legal representatives. In the event that Assignor is unable to fully perform its obligations under this Section 3, Assignor hereby irrevocably designates and appoints Assignee or its assigns and their duly authorized officers and agents as Assignor’s agents and attorneys-in-fact to act for and in Assignor’s behalf and instead of Assignor, to execute and file any registration, application or other document and to do all other lawfully permitted acts in connection with the Purchased

Patents assigned to Assignee hereunder. The foregoing appointment is deemed a power coupled with an interest and is irrevocable.

4. The terms of the Purchase Agreement, including, but not limited to, Assignor's representations, warranties, covenants, agreements and indemnities relating to the Purchased Patents, are incorporated herein by this reference. Nothing in this Assignment shall, or shall be deemed to, modify, expand, supersede or otherwise affect any provisions of the Purchase Agreement (including any representations or warranties) or affect, modify, expand or supersede any of the rights, obligations or remedies of the Parties. Except as otherwise provided in the immediately preceding sentence, the Parties intend that nothing in the Purchase Agreement contradicts or otherwise limits the terms of this Assignment. However, in the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.


[Signature Page Follows]


IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Registered Intellectual Property to be executed by authorized representatives as of the date first written above.

ASSIGNOR:

Place/Date:

Amplix Pharmaceuticals, Inc.
Address: 66 Hudson Boulevard East New York, NY 10001-2192, United States of America

By: 
Name: ANDREW MURATORE
Title: VICE PRESIDENT + SECRETARY

Witness: 
Name: Robert Baxter

ASSIGNEE:

Place/Date:

Basilea Pharmaceutica International AG, Allschwil
Address: Hegenheimermattweg 167b, 4123 Allschwil, Switzerland

By: _____
Name: _____
Title: _____

By: _____
Name: _____
Title: _____

Witness: _____
Name: _____

Witness: _____
Name: _____

IN WITNESS WHEREOF, the parties hereto have caused this Assignment of Registered Intellectual Property to be executed by authorized representative as of the date first written above.

ASSIGNOR:

Place/Date:

Amplyx Pharmaceuticals, Inc.
Address: 66 Hudson Boulevard East New York, NY 10001-2192, United States of America

By: _____
Name: _____
Title: _____


Witness: _____
Name: _____

ASSIGNEE:

Place/Date:


Basilea Pharmaceutica International AG, Allschwil
Address: Hegenheimermattweg 167b, 4123 Allschwil, Switzerland

By: _____
Name: _____
Title: _____

 DocuSigned by:
Jonathan Thwaite
Signer Name: Jonathan Thwaite
Signing Reason: I approve this document
Signing Time: 10-Nov-2023 | 16:16 CET

Witness: _____
Name: _____

By: _____
Name: _____
Title: _____

 DocuSigned by:
Damian Heller
Signer Name: Damian Heller
Signing Reason: I approve this document
Signing Time: 10-Nov-2023 | 06:31 PST

Witness: _____
Name: _____

SCHEDULE A
REGISTERED IP

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407	49748-710.101	United States - (US)	62/595894	12/7/2017	Lapsed - (L)			Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407	49748-710.102	United States - (US)	62/649225	03/28/2018	Lapsed - (L)			Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407A	49748-710.481	A.R.I.P.O. - (AP)	AP/P/2020/012493	12/7/2018	Allowed - (A)			Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407A	49748-710.485	Benin - (BJ)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407A	49748-710.485	Burkina Faso - (BF)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407A	49748-710.485	Cameroon - (CM)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPLXX)
040407A	49748-710.485	Central African Republic - (CF)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPLXX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.485	Chad - (TD)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Comoro Islands - (KM)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Congo - (CG)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Equatorial Guinea - (GQ)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Gabon - (GA)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Guinea - (GN)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Guinea-Bissau - (GW)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Ivory Coast - (CI)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.485	Mali - (ML)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Mauritania - (MR)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Niger - (NE)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	O.A.P.I. - (OA)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Senegal - (SN)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.485	Togo - (TG)	1202000193	12/7/2018	Issued - (G)	20177	12/14/2021	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.591	Eurasian Patent Convention - (EA)	202091255	12/7/2018	Issued - (G)	202091255	7/27/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.591	Russian Federation - (RU)	202091255	12/7/2018	Issued - (G)	202091255	7/27/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.601	Patent Cooperation Treaty - (WO)	PCT/US2018/064609	12/7/2018	Lapsed - (L)			Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Belgium - (BE)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Denmark - (DK)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	European Patent Convention - (EP)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Finland - (FI)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	France - (FR)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Germany - (DE)	18885399.8	12/7/2018	Issued - (G)	602018056721.6	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Great Britain - (GB)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.611	Hong Kong - (HK)	62021027978.7	12/7/2018	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Ireland - (IE)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Italy - (IT)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Netherlands - (NL)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Norway - (NO)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Spain - (ES)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Sweden - (SE)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.611	Turkey - (TR)	18885399.8	12/7/2018	Issued - (G)	3720438	8/30/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.681	Australia - (AU)	2018379077	12/7/2018	Issued - (G)	2018379077	8/10/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.691	Brazil - (BR)	BR1120200111627	12/7/2018	Exam Requested - (E)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.701	Canada - (CA)	3084298	12/7/2018	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.711	China P.R. - (CN)	201880088941.1	12/7/2018	Issued - (G)	ZL2018800889411	8/1/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.731	Israel - (IL)	275121	12/7/2018	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.741	India - (IN)	202017023152	12/7/2018	Issued - (G)	424223	3/6/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.741	India - (IN)	202218056260	9/30/2022	Exam Requested - (E)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.761	Japan - (JP)	2020-550050	12/7/2018	Issued - (G)	7292299	6/8/2023	Amplifyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040407A	49748-710.761	Japan - (JP)	2023-92871	6/6/2023	Exam Requested - (E)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.771	Korea South - (KR)	10-2020-7019209	12/7/2018	Exam Requested - (E)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.781	Mexico - (MX)	MX/a/2020/005927	12/7/2018	Issued - (G)	awaiting	6/14/2023	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.831	United States - (US)	16/770476	12/7/2018	Issued - (G)	11512079	11/29/2022	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407B	49748-710.831	United States - (US)	17/934629	9/23/2022	Published - (P)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040407A	49748-710.841	South Africa - (ZA)	2020/03281	12/7/2018	Issued - (G)	2020/03281	10/25/2023	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040408	49748-711.101	United States - (US)	62/725971	8/31/2018	Lapsed - (L)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.481	A.R.I.P.O. - (AP)	AP/P/2021/013039	8/30/2019	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040408A	49748-711.485	O.A.P.I. - (OA)	1202100093	8/30/2019	Issued - (G)	20177	12/14/2021	Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.591	Eurasian Patent Convention - (EA)	202190590	8/30/2019	Allowed - (A)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.591	Eurasian Patent Convention - (EA)	202390707	3/27/2023	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.601	Patent Cooperation Treaty - (WO)	PCT/US2019/049223	8/30/2019	Lapsed - (L)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.611	European Patent Convention - (EP)	19853628.6	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.681	Australia - (AU)	2019328599	8/30/2019	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.691	Brazil - (BR)	BR1120210038787	8/30/2019	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.701	Canada - (CA)	3110860	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040408A	49748-711.711	China P.R. - (CN)	201980072614.1	8/30/2019	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.711	Hong Kong - (HK)	62021040416.1	10/14/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.731	Israel - (IL)	281140	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.741	India - (IN)	202117010323	8/30/2019	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.761	Japan - (JP)	2021-510464	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.771	Korea South - (KR)	10-2021-7009418	8/30/2019	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.781	Mexico - (MX)	MX/a/2021/002444	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.831	United States - (US)	17/271020	8/30/2019	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040408A	49748-711.841	South Africa - (ZA)	2021/01555	8/30/2019	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.851	Taiwan - (TW)	108131566	9/2/2019	Exam Requested - (E)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040408A	49748-711.871	Argentina - (AR)	P190102493	9/2/2019	Published - (P)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040409	49748-712.101	United States - (US)	62/689535	6/25/2018	Lapsed - (L)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040409	49748-712.102	United States - (US)	62/722539	8/24/2018	Lapsed - (L)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.601	Patent Cooperation Treaty - (WO)	PCT/US2019/038780	6/24/2019	Lapsed - (L)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.611	European Patent Convention - (EP)	19826531.6	6/24/2019	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.681	Australia - (AU)	2019294474	6/24/2019	Pending - (F)			Amplifyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040409A	49748-712.701	Canada - (CA)	3104653	6/24/2019	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.711	China P.R. - (CN)	201980056287.0	6/24/2019	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.761	Japan - (JP)	2020-571542	6/24/2019	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.771	Korea South - (KR)	10-2021-7000794	6/24/2019	Exam Requested - (E)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040409A	49748-712.831	United States - (US)	17/253885	6/24/2019	Issued - (G)	11771688	10/3/2023	Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040410	49748-714.101	United States - (US)	62/858897	6/7/2019	Lapsed - (L)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040410A	49748-714.601	Patent Cooperation Treaty - (WO)	PCT/US2020/036400	6/5/2020	Lapsed - (L)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411	49748-715.101	United States - (US)	62/985274	3/4/2020	Lapsed - (L)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040411A	49748-715.101	United States - (US)	17/908079	3/2/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Australia - (AU)	2021230529	3/2/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Brazil - (BR)	BR112022017653-8	3/2/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Canada - (CA)	3174065	3/2/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	China P.R. - (CN)	202180033043.8	3/2/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	European Patent Convention - (EP)	21765099.3	3/2/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Hong Kong - (HK)	62023074654.2	6/19/2023	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	India - (IN)	202217056899	3/2/2021	Abandoned - (B)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040411A	49748-715.601	Israel - (IL)	296093	3/2/2021	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Japan - (JP)	2022-552405	3/2/2021	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Korea South - (KR)	2022-7034025	3/2/2021	Exam Requested - (E)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Macao - (MO)			New File - (D)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Mexico - (MX)	MX/a/2022/010804	3/2/2021	Published - (P)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	New Zealand - (NZ)	792042	3/2/2021	Pending - (F)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Patent Cooperation Treaty - (WO)	PCT/US2021/020471	3/2/2021	Lapsed - (L)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Russian Federation - (RU)	2022123518	3/2/2021	Exam Requested - (E)			Ampllyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040411A	49748-715.601	Saudi Arabia - (SA)	522440394	3/2/2021	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	Singapore - (SG)	11202252657K	3/2/2021	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	South Africa - (ZA)	2022/10036	3/2/2021	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040411A	49748-715.601	United Arab Emirates - (AE)	P6001759/2022	3/2/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412	49748-716.101	United States - (US)	63/040450	6/17/2020	Lapsed - (L)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.101	United States - (US)	18/002012	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Argentina - (AR)			Abandoned - (B)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Australia - (AU)	2021293911	6/16/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040412A	49748-716.601	Brazil - (BR)	BR112022024988-8	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Canada - (CA)	3187268	6/16/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	China P.R. - (CN)	202180050716.0	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	European Patent Convention - (EP)	21825864.8	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Hong Kong - (HK)	62023074617.9	6/16/2023	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Israel - (IL)	299057	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Japan - (JP)	2022-577084	6/16/2021	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Korea South - (KR)	10-2023-7001328	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)

Docket Number	Former Docket Number	Country	Application Number	Application Date	Status	Patent Number	Grant Date	Owner at PTO
040412A	49748-716.601	Mexico - (MX)	MX/a/2022/016179	6/16/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Patent Cooperation Treaty - (WO)	PCT/US2021/037578	6/16/2021	Lapsed - (L)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Russian Federation - (RU)	2022133022	6/16/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	Singapore - (SG)	11202261008Q	6/16/2021	Exam Requested - (E)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.601	South Africa - (ZA)	2023/00383	6/16/2021	Pending - (F)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)
040412A	49748-716.851	Taiwan - (TW)	110122166	6/17/2021	Published - (P)			Amlyx Pharmaceuticals, Inc. - (AMPL YX)